HAVCR2 and leukemia: Overall, TIM-3 blockade combined with other checkpoint inhibitors, targeted inhibitors, or HMAs may improve the clinical outcome of patients with leukemia; however, more clinical data are required to support the application of TIM-3 inhibitors in leukemia immunotherapy.